U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C40H38F5N3O3S
Molecular Weight 735.805
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RILAPLADIB

SMILES

COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C(SCC5=C(F)C(F)=CC=C5)=CC(=O)C6=C4C=CC=C6

InChI

InChIKey=NNBGCSGCRSCFEA-UHFFFAOYSA-N
InChI=1S/C40H38F5N3O3S/c1-51-22-21-46-19-17-32(18-20-46)47(24-27-9-11-28(12-10-27)29-13-15-31(16-14-29)40(43,44)45)37(50)25-48-35-8-3-2-6-33(35)36(49)23-38(48)52-26-30-5-4-7-34(41)39(30)42/h2-16,23,32H,17-22,24-26H2,1H3

HIDE SMILES / InChI

Molecular Formula C40H38F5N3O3S
Molecular Weight 735.805
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Rilapladib (SB659032) is a potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Inhibition of Lp-PLA2 can reduce peripheral measures of inflammation. Rilapladib has been evaluated for treatment in Alzheimer’s disease and atherosclerosis. Initial results from clinical trials in Alzheimer patients suggests that oral administration of rilapladib may slow down the progression of Alzheimer’s disease. Initial evidence has also been found that inhibition of Lp-PLA2 may attenuate intimal macrophage accumulation and consequently stabilize atherosclerotic plaque.

Approval Year

PubMed

PubMed

TitleDatePubMed
Lipoprotein-associated phospholipase A(2) and atherosclerosis.
2009 Oct
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study.
2012
Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study.
2014 Aug
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:31:10 GMT 2023
Edited
by admin
on Fri Dec 15 16:31:10 GMT 2023
Record UNII
O14CWE893Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RILAPLADIB
INN   USAN  
INN   USAN  
Official Name English
SB-659032
Code English
RILAPLADIB [USAN]
Common Name English
rilapladib [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29703
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C76401
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
INN
8704
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
FDA UNII
O14CWE893Z
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
PUBCHEM
9918381
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
EVMPD
SUB64595
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
ChEMBL
CHEMBL2104981
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
DRUG BANK
DB05119
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
CAS
412950-08-4
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
SMS_ID
100000134795
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID50194281
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
USAN
RR-58
Created by admin on Fri Dec 15 16:31:10 GMT 2023 , Edited by admin on Fri Dec 15 16:31:10 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY